# James N. Ingle

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/james-n-ingle/

## Facts

| Field | Value |
| --- | --- |
| Citations | 55,419 |
| Field | Estrogen and related hormone effects |
| h-index | 96 |
| i10-index | 334 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5083904553 |
| ORCID iD | https://orcid.org/0000-0003-1257-7731 |
| Works | 731 |

## Researcher papers

- [Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-plus-adjuvant-chemotherapy-for-operable-her2-positive-breast-cancer/)
- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015](https://scholariq.org/papers/tailoring-therapies-improving-the-management-of-early-breast-cancer-st-gallen/)
- [A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer](https://scholariq.org/papers/a-randomized-trial-of-letrozole-in-postmenopausal-women-after-five-years-of/)
- [Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741](https://scholariq.org/papers/randomized-trial-of-dose-dense-versus-conventionally-scheduled-and-sequential/)
- [Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial](https://scholariq.org/papers/prognostic-and-predictive-value-of-the-21-gene-recurrence-score-assay-in/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline](https://scholariq.org/papers/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer/)
- [Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging](https://scholariq.org/papers/trends-in-mastectomy-rates-at-the-mayo-clinic-rochester-effect-of-surgical-year/)

## Researcher topics

- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.